Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy

BACKGROUND: Multikinase inhibitors (MKIs) sunitinib and sorafenib have become a standard of care for metastatic renal cell carcinoma (mRCC). This study assessed safety and treatment patterns for these agents in a real-world clinical practice setting in Italy. METHODS: A retrospective medical record...

Descripción completa

Detalles Bibliográficos
Autores principales: Porta, Camillo, Paglino, Chiara, Imarisio, Ilaria, Canipari, Cinzia, Chen, Kristina, Neary, Maureen, Duh, Mei Sheng
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079688/
https://www.ncbi.nlm.nih.gov/pubmed/21435216
http://dx.doi.org/10.1186/1471-2407-11-105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079688/
https://www.ncbi.nlm.nih.gov/pubmed/21435216
http://dx.doi.org/10.1186/1471-2407-11-105

Ejemplares similares